Novo Nordisk spends up to $1.64bn on US biotech startups
Novo Nordisk taps Flagship Pioneering portfolio companies Omega Therapeutics and Cellarity as obesity drugs competition intensifies.
08 January 2024
08 January 2024
Novo Nordisk taps Flagship Pioneering portfolio companies Omega Therapeutics and Cellarity as obesity drugs competition intensifies.
Intellia Therapeutics announced its clinical goals for the next few years, pushing development for its late-stage ATTR asset.
The deal aligns with Boehringer Ingelheim’s strategy to create breakthrough therapies in this disease area.
Menarini’s subsidiary Stemline will receive upfront and milestone payments, with a potential value exceeding $500m, along with royalties from sales.
The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.
Zelsuvmi's efficacy was proven in two Phase III clinical trials, B-SIMPLE 4 and B-SIMPLE 2.
The programme will facilitate the import of cost-effective prescription drugs from Canada, ensuring safety and compliance.
The new facility in Indianapolis will increase the company’s RLT production capacity to 250,000 doses annually from 2024 onwards.
Genomics has been identified as the top emerging pharmaceutical industry trend for 2024, with its growth attributed to the increasing prevalence of chronic diseases, plummeting DNA sequencing costs, and increasing funding for genomics. Despite an optimistic outlook for 2024, the industry growth is predicted to be below 2022 levels primarily due to geopolitical conflicts, inflation, and drug pricing pressures.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Give your business an edge with our leading industry insights.